Pethema Multiple Myeloma 2000
Pethema Multiple Myeloma 2000
The study objectives are to investigate the toxicity and the BUMEL response rate; in patients
 who reach the CR after autotransplantation, investigate if negativization of IF, influences
 in disease evolution; in patients in PR after autotransplantation, analyze if the second
 intensive procedure is capable of increasing the response rate and increasing the survival so
 that patients who reached the CR with the first transplantation; Patients with MM primarily
 resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients
 submitted to double transplantation, control the efficacy of the second transplantation in
 front of allogenic transplantation.
Inclusion Criteria:

 -  Less 70 years

 -  ECOG 0-2

 -  Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia,
 extramedulary plasmocytoma, creatinine >2 mg/dl).

 -  No previous chemotherapy

 Exclusion Criteria:

 -  >70 years

 -  ECOG 3-4

 -  myeloma quiescent

 -  cardiopathy

 -  liver disfunction

 -  HIV+

 -  Hepatitis B-C +

 -  Previous chemotherapy